Pharmacokinetics

Pharmacokinetics (PK) is a fundamental branch of pharmacology that describes what the body does to a drug after administration. It focuses on the movement of drugs within the body, tracking how a drug is absorbed, distributed, metabolized, and excreted commonly known as the ADME process.

Understanding pharmacokinetics is essential for determining appropriate dosing, frequency, and duration of therapy to achieve optimal therapeutic effects while minimizing toxicity.

---

Definition

Pharmacokinetics refers to the quantitative study of the time course of drugs within the body. It involves mathematical models to describe the rates at which a drug moves between compartments in the body and is eventually eliminated.

Pharmacokinetics = What the body does to the drug

---

Pharmacokinetic Processes (ADME)

The four primary processes of pharmacokinetics are:

1.     Absorption

2.     Distribution

3.     Metabolism (Biotransformation)

4.     Excretion

Pharmacokinetic Processes (ADME)

The four primary processes of pharmacokinetics are:

1.     Absorption

2.     Distribution

3.     Metabolism (Biotransformation)

4.     Excretion

---

1. Absorption

Definition:
Absorption is the process by which a drug moves from its site of administration into the systemic circulation (bloodstream).

Key Routes of Administration:

·         Oral (PO) – most common

·         Intravenous (IV) – direct into the bloodstream

·         Intramuscular (IM)

·         Subcutaneous (SC)

·         Sublingual

·         Rectal

·         Transdermal

·         Inhalational

Factors Affecting Absorption:

·         Drug solubility and formulation

·         pH and pKa of the drug

·         Gastrointestinal (GI) motility

·         Presence of food in the stomach

·         Blood flow to absorption site

·         Surface area of absorption

Bioavailability (F):

·         It is the fraction of an administered dose that reaches systemic circulation in its active form.

·         For IV administration, bioavailability is 100%.

·         Oral administration often results in reduced bioavailability due to first-pass metabolism.

---

2. Distribution

Definition:
Distribution is the process by which the drug is dispersed throughout the body fluids and tissues after entering the bloodstream.

Key Determinants of Distribution:

·         Blood flow to tissues

·         Plasma protein binding (e.g., albumin)

·         Lipid solubility of the drug

·         Capillary permeability

·         Tissue binding

Volume of Distribution (Vd):

·         A theoretical volume that relates the amount of drug in the body to the plasma concentration.

·         Higher Vd indicates greater distribution into tissues.

Vd=Total amount of drug in the bodyPlasma drug concentrationVd = \frac{\text{Total amount of drug in the body}}{\text{Plasma drug concentration}}Vd=Plasma drug concentration Total amount of drug in the body​

---

3. Metabolism (Biotransformation)

Definition:
Metabolism refers to the chemical alteration of the drug in the body, mainly by liver enzymes, converting it into more water-soluble metabolites for easier excretion.

Phases of Metabolism:

·         Phase I: Modification reactions (oxidation, reduction, hydrolysis)

o    Mainly via the Cytochrome P450 (CYP450) enzyme system

o    Results in activation, inactivation, or conversion to toxic metabolites

·         Phase II: Conjugation reactions (glucuronidation, sulfation, acetylation)

o    Makes metabolites more water-soluble

First-Pass Effect:

·         Drugs absorbed via the GI tract first pass through the liver via the portal vein, where they may be metabolized before reaching systemic circulation.

·         This reduces the effective concentration of the drug.

---

4. Excretion

Definition:
Excretion is the process of removing drugs and their metabolites from the body.

Primary Routes of Excretion:

·         Renal (urine) – major route

·         Biliary (feces)

·         Lungs (volatile substances)

·         Sweat, saliva, breast milk

Renal Excretion Processes:

1.     Glomerular Filtration

2.     Tubular Secretion

3.     Tubular Reabsorption

Clearance (Cl):

·         The volume of plasma from which a drug is completely removed per unit time.

Cl=Rate of eliminationPlasma drug concentrationCl = \frac{\text{Rate of elimination}}{\text{Plasma drug concentration}}Cl=Plasma drug concentration Rate of elimination​

---

Pharmacokinetic Parameters

1.     Half-life (t1/2):

o    Time required for the plasma concentration of a drug to reduce by half.

o    Indicates how long a drug stays in the body.

2.     Area Under the Curve (AUC):

o    Represents the total drug exposure over time.

3.     Cmax and Tmax:

o    Cmax: Maximum plasma concentration achieved.

o    Tmax: Time taken to reach Cmax.

4.     Bioavailability (F):

o    Percentage of the administered drug reaching systemic circulation.

5.     Steady-State Concentration (Css):

o    Achieved when the rate of drug administration equals the rate of elimination.

6.     Therapeutic Window:

o    The concentration range where the drug is effective without being toxic.

Factors Influencing Pharmacokinetics

1.     Age

o    Neonates and elderly may have reduced metabolism and excretion.

2.     Genetics

o    Variations in metabolic enzymes (pharmacogenomics)

3.     Body Composition

o    Fat content, body water affect distribution.

4.     Disease States

o    Liver and kidney dysfunction impact metabolism and excretion.

5.     Drug Interactions

o    Some drugs induce or inhibit enzymes affecting metabolism.

6.     Diet and Lifestyle

o    Food, alcohol, smoking can influence drug metabolism.

---

Clinical Significance of Pharmacokinetics

·         Dose Calculation: Determines correct dose and interval.

·         Therapeutic Drug Monitoring: Ensures plasma levels stay within therapeutic range.

·         Understanding Drug Interactions: Predicts effects when combining drugs.

·         Individualized Therapy: Adjust dosing in liver/kidney impairment.

·         Bioequivalence Studies: For generic drug approval.

⧪Dose Calculation: Dose calculation is essential to ensure that patients receive the correct amount of medication based on their condition, body parameters, and route of administration. Administering the wrong dose can lead to ineffectiveness or toxicity.

     ￫ Common Methods of Dose Calculation

1. Standard Dose Calculation
• Based on recommended doses in mg, g, mcg as per adult standards.
• Example: Paracetamol 500 mg every 6 hours.
2. Weight-Based Dose Calculation
• Formula:

Dose = Weight (kg) × Dose per kg

• Example: If the dose is 10 mg/kg for a 20 kg child:

Dose = 20 kg × 10 mg = 200 mg

3. Body Surface Area (BSA) Based Calculation
• Common for chemotherapy or critical care drugs.
• BSA (m²) is calculated via:

BSA = √[(Height(cm) × Weight(kg))/3600]

• Then:

Dose = BSA (m²) × Dose per m²

4. Age-Based Calculation
• Pediatric doses can sometimes be derived using age:
• Young's Rule:

Dose = (Age / (Age + 12)) × Adult dose

• Clark's Rule:

 

Dose = (Weight (lb) / 150) × Adult dose

5. Dose Calculation for IV Infusion (Drip Rate)
• Formula:

Flow rate (ml/hr) = (Volume to be infused × Drop factor) / Time (minutes)

 

ml/hr = Total volume (ml) / Total time (hr)

6. Dilution Calculations
• Using the Formula of Concentration:

C1 × V1 = C2 × V2

Where:

• C1 = Initial concentration
• V1 = Initial volume
• C2 = Final concentration
• V2 = Final volume

---

🔹 Example Calculations

1. Paracetamol for a Child
• Dose: 15 mg/kg
• Weight: 25 kg

Dose = 25 kg × 15 mg = 375 mg

2. Chemotherapy Example
• Drug dose: 100 mg/m²
• Patient's BSA: 1.5 m²

 

Dose = 100 mg/m² × 1.5 m² = 150 mg

3. IV Drip Rate
• 1000 ml over 8 hours

Rate = 1000 ml / 8 hr = 125 ml/hr

---

🔹 Key Points

• Always check drug references for standard doses.
• Consider patient-specific factors: age, weight, renal/liver function.
• Always use appropriate formulas to minimize dosing errors.
• Double-check your calculations before administration.

 

---

  ⧪Definition

Therapeutic Drug Monitoring (TDM) is a clinical practice of measuring specific drug concentrations in a patient's bloodstream to ensure that the dosage remains within a targeted therapeutic range. The aim is to optimize the drug’s effectiveness while minimizing potential toxicity or side effects.

---

Importance of TDM

Some drugs have:

• A narrow therapeutic index (small difference between effective and toxic doses).
• Significant variability in how patients absorb, distribute, metabolize, and eliminate drugs.
• High risk of toxicity or subtherapeutic levels if not properly monitored.

---

 Objectives of TDM

1. Optimize Drug Dosage — Ensure the drug concentration is effective but not toxic.
2. Improve Clinical Outcomes — Achieve better disease control and symptom relief.
3. Avoid Adverse Effects — Reduce the risk of drug toxicity.
4. Assess Patient Compliance — Detect non-adherence to prescribed medication.
5. Monitor Drug Interactions — Adjust doses in polypharmacy scenarios.

---

 Drugs Commonly Monitored via TDM

• Antiepileptics: Phenytoin, Carbamazepine, Valproic acid
• Immunosuppressants: Cyclosporine, Tacrolimus
• Antibiotics: Vancomycin, Gentamicin
• Psychotropic Drugs: Lithium, Clozapine
• Cardiac Drugs: Digoxin, Theophylline

---

 Phases of TDM Process

1. Patient Evaluation
• Assess age, weight, organ function (kidney, liver), and comorbidities.
• Understand patient compliance and medication history.
2. Sample Collection
• Correct timing is crucial:
• Trough levels: Just before the next dose.
• Peak levels: After the drug has been administered (when absorption is complete).
• Standardized methods to ensure accurate sampling.
3. Laboratory Analysis
• Use of analytical techniques:
• Immunoassays
• Chromatography methods (HPLC, LC-MS/MS)
• Ensures precise measurement of drug levels.
4. Interpretation of Results
• Compare measured levels to established therapeutic ranges.
• Factor in patient-specific parameters like age, organ function, and drug interactions.
5. Clinical Decision and Dose Adjustment
• Modify the dose, frequency, or form of the drug.
• Re-monitor as necessary.
6. Documentation and Follow-Up
• Keep records of drug levels, dose changes, and patient responses.
• Continuous monitoring in long-term therapies.

---

 Factors Affecting Drug Levels

• Age (elderly, pediatric)
• Body weight and fat composition
• Renal and liver function
• Drug interactions
• Genetic factors affecting metabolism (Pharmacogenomics)
• Patient compliance
• Disease conditions

---

 Advantages of TDM

• Ensures personalized treatment.
• Prevents under dosing and overdosing.
• Improves medication adherence.
• Prevents drug toxicity.
• Enhances therapeutic success.

---

 Limitations of TDM

• Not suitable for all drugs (only drugs with narrow therapeutic windows or variable pharmacokinetics).
• Requires specialized laboratory facilities.
• Interpretation requires clinical expertise.
• Sample collection errors can affect accuracy.

⧪ Understanding of Drug Interaction:

    Drug interactions occur when the effect of one drug is altered by the presence of another substance such as:

·         Another drug

·         Food

·         Alcohol

·         Supplements (herbal products, vitamins)

These interactions can:

·         Increase drug effects (synergism)

·         Decrease drug effects (antagonism)

·         Cause unexpected side effects

---

 Types of Drug Interactions

Type	Description	Examples
Drug-Drug Interactions (DDI)	Interaction between two or more drugs.	Warfarin + NSAIDs → Bleeding risk
Drug-Food Interactions	Food affects the drug's absorption or metabolism.	Grapefruit juice + Statins → Toxicity
Drug-Alcohol Interactions	Alcohol alters drug metabolism or effect.	Metronidazole + Alcohol → Severe nausea
Drug-Disease Interactions	A pre-existing condition alters drug effects.	Beta-blockers in asthma → Worsened breathing
Drug-Herbal Interactions	Herbs affect the efficacy or toxicity of drugs.	St. John’s Wort + Antidepressants → Reduced effectiveness

---

Mechanisms of Drug Interactions

1.      Pharmacokinetic Interactions
Affect Absorption, Distribution, Metabolism, or Excretion (ADME) of drugs.

o    Absorption: Antacids reduce absorption of some antibiotics like tetracycline.

o    Distribution: One drug displaces another from protein-binding sites (e.g., Valproic acid displacing phenytoin).

o    Metabolism:

§  Enzyme induction increases drug metabolism (e.g., Rifampin induces liver enzymes reducing oral contraceptive efficacy).

§  Enzyme inhibition decreases metabolism (e.g., Erythromycin inhibits metabolism of Theophylline → toxicity).

o    Excretion: Some drugs alter renal excretion (e.g., Probenecid inhibits excretion of penicillin, prolonging its effect).

2.      Pharmacodynamic Interactions
Occur when two drugs influence the same physiological system.

o    Synergistic effect: Alcohol + CNS depressants → Excessive sedation.

o    Antagonistic effect: Beta-blockers + Beta-agonists → Reduced efficacy of both.

---

Clinical Significance of Drug Interactions

·         Beneficial Interactions

o    Combination therapies (e.g., HIV treatment using multiple antiretrovirals).

o    Cancer chemotherapy regimens.

·         Harmful Interactions

o    Increased toxicity (e.g., Aminoglycosides + Loop diuretics → Hearing loss).

o    Treatment failure (e.g., Antacids reducing absorption of antifungal medications).

---

 Factors Influencing Drug Interactions

·         Age (elderly more susceptible)

·         Genetics (e.g., polymorphisms in drug-metabolizing enzymes)

·         Polypharmacy (multiple medications increase risk)

·         Organ function (liver and kidney diseases)

·         Dietary habits

·         Alcohol and tobacco use

---

Prevention of Drug Interactions

1.  Medication Review: Regular assessment of all medications including OTC and herbal supplements.

2.      Monitoring Therapy: Close monitoring of drug levels, side effects, and therapeutic effects.

3.      Patient Education: Inform patients about potential food, alcohol, and drug interactions.

4.      Dose Adjustments: Modify doses if an interaction is unavoidable.

5.      Use of Interaction Checkers: Tools and software to predict possible drug interactions.

---

Common Drug Interactions Examples

·         Warfarin + Antibiotics: Increased bleeding risk.

·         ACE inhibitors + Potassium supplements: Hyperkalemia.

·         SSRIs + MAO inhibitors: Risk of serotonin syndrome.

·         Grapefruit juice + Calcium channel blockers: Increased drug concentration leading to toxicity.

⧪ Individualized Therapy

 Definition

Individualized Therapy, also called Personalized Medicine, refers to the process of tailoring medical treatment to the unique characteristics of each patient. It involves customizing drug selection, dosage, and treatment duration based on the patient's:

·         Genetic makeup

·         Disease characteristics

·         Lifestyle

·         Environment

·         Comorbid conditions

The goal is to maximize therapeutic benefits while minimizing risks and side effects.

---

 Key Components of Individualized Therapy

1.      Pharmacogenomics

o    Study of how a person’s genes affect their response to drugs.

o    Example: Patients with certain CYP2C19 gene variations may poorly metabolize Clopidogrel, reducing its efficacy.

2.      Patient-Specific Factors

o    Age, weight, gender

o    Organ function (liver, kidney)

o    Disease stage and severity

o    Concurrent medications

o    Allergies and sensitivities

3.      Biomarker Testing

o    Identification of biological markers to predict drug response.

o    Example: HER2 testing in breast cancer helps guide use of trastuzumab.

4.      Lifestyle and Environmental Factors

o    Diet, alcohol, and tobacco use

o    Physical activity

o    Occupational exposures

5.      Therapeutic Drug Monitoring (TDM)

o    Measuring drug levels in blood to adjust dosage precisely (e.g., Vancomycin, Phenytoin).

---

Approaches to Individualized Therapy

Approach	Description	Example
Genotype-Guided Therapy	Drug choice and dose based on genetic profile	Warfarin dosing adjusted by VKORC1 and CYP2C9 genotyping
Phenotype-Based Therapy	Customizing therapy based on observable traits	Insulin dosage based on blood glucose monitoring
Therapeutic Drug Monitoring	Adjusting drug doses by measuring plasma drug levels	Digoxin, Lithium
Disease-Specific Tailoring	Treatment adjusted by disease characteristics	Cancer treatments based on tumor markers

---

 Advantages of Individualized Therapy

·         Improved efficacy of treatment

·         Reduced risk of side effects and toxicity

·         Optimized dosing

·         Better patient adherence due to fewer adverse effects

·         Cost-effective by avoiding ineffective treatments

---

 Challenges in Individualized Therapy

·         High cost of genetic and biomarker testing

·         Limited access to advanced diagnostic tools in some regions

·         Need for clinical expertise to interpret genetic and biomarker data

·         Ethical and privacy concerns with genetic data

---

Examples of Individualized Therapy in Practice

·         Oncology: Targeted therapies (e.g., EGFR inhibitors in lung cancer with EGFR mutations)

·         Psychiatry: Adjusting antidepressant therapy based on metabolic enzyme activity (e.g., CYP450)

·         Cardiology: Warfarin dosing adjusted by genetic factors affecting metabolism.

·         Infectious Disease: Antibiotic dosing adjusted in renal impairment.

---

Future of Individualized Therapy

·         Precision Medicine Initiatives globally to integrate genomics into routine care.

·         Use of Artificial Intelligence and big data to predict treatment outcomes.

·         Development of gene editing and cell-based therapies for ultra-personalized care.

⧪ Bioequivalence (BE) studies

Definition

Bioequivalence (BE) studies are scientific tests that compare the bioavailability of the same active pharmaceutical ingredient (API) in two different drug formulations—typically a generic drug versus an innovator (brand-name) drug.

If the two products show similar bioavailability (rate and extent of absorption), they are considered bioequivalent, meaning they will have comparable safety, efficacy, and therapeutic effect.

---

Purpose of Bioequivalence Studies

·         To ensure that generic drugs perform the same as their brand-name counterparts.

·         Required for regulatory approval by agencies like:

o    US FDA (United States Food and Drug Administration)

o    EMA (European Medicines Agency)

o    CDSCO (India’s Central Drugs Standard Control Organization)

·         Ensures cost-effective alternatives without compromising therapeutic quality.

---

Key Terms

·         Bioavailability: The proportion of an administered dose of a drug that reaches systemic circulation in an active form.

·         Pharmacokinetics (PK): Study of drug absorption, distribution, metabolism, and excretion (ADME).

·         Cmax: Maximum concentration of the drug in plasma.

·         Tmax: Time to reach maximum plasma concentration.

·         AUC (Area Under Curve): Total drug exposure over time.

---

 Criteria for Bioequivalence

To declare two products bioequivalent, their Cmax, Tmax, and AUC should fall within an 80% to 125% range of the reference product (with 90% confidence intervals), according to most regulatory guidelines.

---

Process of Conducting Bioequivalence Studies

1.      Study Design

o    Crossover Design: Commonly used where the same subjects receive both test and reference drugs with a washout period in between.

o    Parallel Design: Used when crossover is not feasible (e.g., drugs with long half-lives).

2.      Subject Selection

o    Usually healthy volunteers aged 18-55 years.

o    Inclusion and exclusion criteria to ensure safety.

3.      Dosing

o    Single dose or multiple doses depending on drug characteristics.

4.      Sample Collection

o    Blood samples collected at multiple time points post-dosing.

5.      Pharmacokinetic Analysis

o    Measure drug concentration in plasma/serum.

o    Plot plasma concentration vs. time curves.

o    Calculate PK parameters: Cmax, Tmax, AUC.

6.      Statistical Evaluation

o    Use ANOVA (Analysis of Variance).

o    90% confidence intervals for the ratio of the means (Test/Reference) for Cmax and AUC must lie within 80%-125%.

7.      Reporting and Regulatory Submission

o    Detailed report including study design, PK data, statistical analysis.

o    Submitted to regulatory agencies for drug approval.

---

 Types of Bioequivalence Studies

·         In Vivo Studies: Conducted in humans to compare drug absorption.

·         In Vitro Studies: Dissolution testing under laboratory conditions; often used as a preliminary step.

·         Waivers (Biowaivers): Sometimes granted for highly soluble drugs (BCS Class I) based on dissolution studies without in vivo testing.

---

 Biopharmaceutical Classification System (BCS)

Drugs are classified into:

·         Class I: High solubility, high permeability (likely eligible for biowaiver)

·         Class II: Low solubility, high permeability

·         Class III: High solubility, low permeability

·         Class IV: Low solubility, low permeability

BCS classification influences the need and complexity of bioequivalence studies.

---

 Importance of Bioequivalence Studies

·         Guarantees therapeutic equivalence of generics.

·         Facilitates drug affordability and accessibility.

·         Prevents substandard or counterfeit medicines in the market.

·         Ensures patient confidence in generic medicines.

---

 Challenges in Bioequivalence Studies

·         Variability in metabolism between individuals.

·         Difficult for narrow therapeutic index drugs.

·         Expensive and time-consuming studies.

·         Ethical considerations in human trials.

---

 Examples of Drugs Requiring BE Studies

·         Antiepileptics: Phenytoin, Carbamazepine

·         Cardiac drugs: Digoxin

·         Immunosuppressants: Cyclosporine

·         Antibiotics: Ciprofloxacin

Mathematical Models in Pharmacokinetics

1.     One-Compartment Model: Assumes body acts as a single uniform compartment.

2.     Two-Compartment Model: Divides body into central (blood and organs) and peripheral (tissues) compartments.

3.     Non-Compartmental Analysis: Uses statistical models without assuming compartments.

---

Applications in Drug Development

·         Determines optimal drug formulation.

·         Predicts behavior of new drugs.

·         Assists in the design of controlled-release formulations.

·         Establishes dosing in special populations (e.g., children, elderly).

---

Conclusion

Pharmacokinetics is an essential aspect of clinical pharmacology and therapeutics. Understanding how drugs are absorbed, distributed, metabolized, and excreted enables healthcare providers to design safe and effective treatment regimens tailored to individual patient needs.

By integrating pharmacokinetic principles with pharmacodynamics, clinicians can maximize therapeutic efficacy, minimize toxicity, and achieve personalized medicine.

---